← Leaderboards
J William Lindsey
University Of Texas Hlth Sci Ctr Houston
$31,806
Attributed
$31,806
Total exposure
4
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$31,806 · 4
By mechanism
M01$31,806 · 4
Top collaborators
No co-investigators on record.
Most similar at University Of Texas Hlth Sci Ctr Houston
Same institution · by research overlap
- Frederick A Moore$6,785,208
- Chinnaswamy Jagannath$18,759,576
- Joy Marie Schmitz$16,485,851
- Ponnada A Narayana$19,017,319
- Ananth V Annapragada$7,084,879
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationMultiple SclerosisDrug Screening /EvaluationClinical TrialsNervous System Disorder ChemotherapyClinical ResearchCopolymer IDrug Adverse EffectRelapse /RecurrenceImmunosuppressiveLongitudinal Human StudyMedical ComplicationNervous System Disorder DiagnosisPathologic ProcessPatient Oriented ResearchMagnetic Resonance ImagingImmunopathology ChemotherapyRemission /RegressionBrain Imaging /Visualization /Scanning
Grant awards (9)
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS: OPEN LABEL STUDY$3,783
M01 · FY2005 · RR
Copaxone in patients with multiple sclerosis: open label study$8,606
M01 · FY2004 · RR
Glatiramer acetate in primary progressive MS$4,303
M01 · FY2004 · RR
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY$0
M01 · FY2002 · RR
Efficacy, tolerability, &safety of glatiramer acetate in multiple sclerosis$0
M01 · FY2002 · RR
Efficacy, tolerability, &safety of glatiramer acetate in multiple sclerosis$0
M01 · FY2001 · RR
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY$0
M01 · FY2001 · RR
COPAXONE IN PATIENTS WITH MULTIPLE SCLEROSIS--OPEN LABEL STUDY$15,114
M01 · FY2000 · RR
Efficacy, tolerability, &safety of glatiramer acetate in multiple sclerosis$0
M01 · FY2000 · RR